Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,728
  • Shares Outstanding, K 36,582
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -32,140 K
  • 60-Month Beta 2.37
  • Price/Sales 4.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +12.74%
on 06/22/20
1.4200 -12.67%
on 06/12/20
-0.4599 (-27.05%)
since 06/10/20
3-Month
0.6699 +85.12%
on 04/13/20
3.5900 -65.46%
on 06/10/20
+0.5901 (+90.78%)
since 04/09/20
52-Week
0.6200 +100.02%
on 04/07/20
3.5900 -65.46%
on 06/10/20
-0.7999 (-39.21%)
since 07/10/19

Most Recent Stories

More News
Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been...

CRIS : 1.2282 (-1.74%)
Curis Announces $17.5 Million Registered Direct Offering

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into definitive...

CRIS : 1.2282 (-1.74%)
Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration...

CRIS : 1.2282 (-1.74%)
Curis: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $9.7 million in its first quarter.

CRIS : 1.2282 (-1.74%)
Curis Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first...

CRIS : 1.2282 (-1.74%)
Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release...

CRIS : 1.2282 (-1.74%)
Curis to Present at 19th Annual Needham Virtual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...

CRIS : 1.2282 (-1.74%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2020, the independent Compensation...

CRIS : 1.2282 (-1.74%)
Curis: 4Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $8.6 million in its fourth quarter.

CRIS : 1.2282 (-1.74%)
Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year...

CRIS : 1.2282 (-1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CRIS with:

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

2nd Resistance Point 1.3869
1st Resistance Point 1.3185
Last Price 1.2282
1st Support Level 1.1908
2nd Support Level 1.1315

See More

52-Week High 3.5900
Fibonacci 61.8% 2.4555
Fibonacci 50% 2.1050
Fibonacci 38.2% 1.7545
Last Price 1.2282
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar